Pivotal Bio Venture Partners Investment Advisor LLC Vaxcyte, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $109 Million
- Q4 2024
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 703,834 shares of PCVX stock, worth $50.1 Million. This represents 53.0% of its overall portfolio holdings.
Number of Shares
703,834
Previous 639,539
10.05%
Holding current value
$50.1 Million
Previous $73 Million
21.09%
% of portfolio
53.0%
Previous 57.56%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$851 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$753 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$708 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$618 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$442 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.22B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...